{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-084428","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.507510+00:00","generated_at":"2026-05-23T12:26:45.733164+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"NewAmsterdam Pharma appoints Adele Gulfo as independent director","bullets":["Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.","Granted options for 50,700 ordinary shares at $16.06/share, vesting over 3 years with 33% on first anniversary.","Granted 10,860 RSUs vesting in equal thirds over three years from April 15, 2025.","Gulfo led launches of Lipitor and Crestor; oversaw $12B+ revenue at Pfizer's U.S. primary care unit.","Appointment adds commercial expertise as company prepares for potential obicetrapib launch in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-084428","json":"https://secwatch.observer/filing/0001193125-25-084428.json","markdown":"https://secwatch.observer/filing/0001193125-25-084428.md","text":"https://secwatch.observer/filing/0001193125-25-084428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/0001193125-25-084428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/d924591d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T12:26:45.733164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bf13c8b71","claim":"Adele Gulfo was appointed as Director at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/0001193125-25-084428-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}